Founded in 2016, Chongqing Precision Biotech Co., Ltd. is a high-tech enterprise jointly established by a technical team which leaded by famous precision medicine scientist Professor Qian Cheng and Chongqing Zhifei Biological Products Co., Ltd. (also known as Zhirui Investment). Taking cell therapy technology research as its starting point, Chongqing Precision engaged in the development and application of gene and cell drugs, and is determined to become a global, innovative and pioneering biomedical enterprise.

Adhering to the core concept of "keep improving and be meticulous", we focus on scientific research and continuously innovates. As of April 2023, we established R&D cooperation and expert exchange mechanisms with 7 overseas institutes and 19 domestic universities, bringing together more than 20 experts and scholars, and over 300 R&D elite team members.We set up industrial technology research institute, postdoctoral workstation and Haizhi workstation. We have been approved as a new high-end research and development institution, key laboratory, engineering research center, engineering technology research center, regional cell preparation center and other platform construction units in Chongqing. We have built an 18,000-square-meter upstream and downstream integrated platform covering the development of cellular drugs, which can support the pre-clinical research, technological research and development, analytical testing and technological production of drugs IND and NDA.

       As a technology innovation enterprise, relying on strong research and development and transformation capabilities, we have  continuously achieved breakthrough innovations in core technologies and cutting-edge fields.With more than 20 years’ experience in the field,our R&D team has acquired core technologies of cell therapy and mastered the key technologies of CAR-T cell therapy.We have applied for 38 patents, and carried out patent layout in developed countries and regions. We currently focus on the application of more than 10 CAR-T research and development pipeline for leukemia, lymphoma, myeloma, gastrointestinal cancer, lung cancer, liver cancer, breast cancer, and pancreatic cancer. We obtained 4 Class I biological CAR-T new drugs and 9 indications of implied license. Our registered clinical trials are progressing smoothly and have achieved excellent clinical data, realizing the first breakthrough in CAR-T technology for the treatment of solid tumors such as colorectal cancer and kidney cancer.